Treatment of hyperlipidaemia with acipimox

References

• Aberg H., Lithell H., Selinius I., Hedstrand H. Serum triglycerides are a risk factor for myocardial infarction but not for angina pectoris: results from a 10-year follow-up of Uppsala Primary Prevention Study. Atherosclerosis 1985; 54: 89–971. Aberg H., Lithell H., Selinius I., Hedstrand H. Serum triglycerides are a risk factor for myocardial infarction but not for angina pectoris: results from a 10-year follow-up of Uppsala Primary Prevention Study. Atherosclerosis 1985; 54: 89–97
   PubMed Web of Science ®Google Scholar
• Ball M. J., Vella M., Rechless J. P. D., Jones D. B., Stirling C., Mann J. I., Galton D. Acipimox in the treatment of patients with hyperlipidaemia: a double-blind trial. Eur. J. Pharmacol. 1986; 31: 201–2042. Ball M. J., Vella M., Rechless J. P. D., Jones D. B., Stirling C., Mann J. I., Galton D. Acipimox in the treatment of patients with hyperlipidaemia: a double-blind trial. Eur. J. Pharmacol. 1986; 31: 201–204
   Web of Science ®Google Scholar
• Cambieu R, Jacqueson A., Richard J. L., Warnet J. M., Ducimetieve D., Claude J. R. Is the level of serum triglyceride a significant predictor of coronary death in ‘normocholesterolemic’ subjects?. Am. J. Epidemiol. 1986; 124: 624–6323. Cambieu R, Jacqueson A., Richard J. L., Warnet J. M., Ducimetieve D., Claude J. R. Is the level of serum triglyceride a significant predictor of coronary death in ‘normocholesterolemic’ subjects?. Am. J. Epidemiol. 1986; 124: 624–632
   PubMed Web of Science ®Google Scholar
• Carlson L. A., Botiger L. E. Risk factors for ischaemic heart disease in men and women: results of the 19-year follow-up of the Stockholm Prospective Study. Acta Med. Scand. 1985; 218: 207–2114. Carlson L. A., Botiger L. E. Risk factors for ischaemic heart disease in men and women: results of the 19-year follow-up of the Stockholm Prospective Study. Acta Med. Scand. 1985; 218: 207–211
   PubMed Web of Science ®Google Scholar
• Castelli W. P. The triglyceride issue: a view from Framingham. Am. Heart J. 1986; 112: 432–4375. Castelli W. P. The triglyceride issue: a view from Framingham. Am. Heart J. 1986; 112: 432–437
   PubMed Web of Science ®Google Scholar
• Castelli W. P., Garrison R. J., Wilson P. W.R, Abbot R. D., Kalousdian S., Kannel W. B. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. J.A.M.A. 1986; 256: 2835–28386. Castelli W. P., Garrison R. J., Wilson P. W.R, Abbot R. D., Kalousdian S., Kannel W. B. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. J.A.M.A. 1986; 256: 2835–2838
   PubMed Web of Science ®Google Scholar
• Fuccella L. M., Goldaniga G., Lovisolo P. P., Maggi E., Musatti L., Mandelli V., Sirtori C. R. Inhibition of lipolysis in man by nicotinic acid and by acipimox. Clin. Pharmacol. Thec 1980; 28: 790–7957. Fuccella L. M., Goldaniga G., Lovisolo P. P., Maggi E., Musatti L., Mandelli V., Sirtori C. R. Inhibition of lipolysis in man by nicotinic acid and by acipimox. Clin. Pharmacol. Thec 1980; 28: 790–795
   PubMed Web of Science ®Google Scholar
• Gordon T., Castelli W. P., Hjortland M. C., Kannell W. B., Dawber T. R. High-density lipoprotein as a protective factor against coronary heart disease. Am. J. Med. 1977; 62: 707–7148. Gordon T., Castelli W. P., Hjortland M. C., Kannell W. B., Dawber T. R. High-density lipoprotein as a protective factor against coronary heart disease. Am. J. Med. 1977; 62: 707–714
   PubMed Web of Science ®Google Scholar
• Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. J.A.M.A. 1984; 251: 3519. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. J.A.M.A. 1984; 251: 351
   PubMed Web of Science ®Google Scholar
• Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. J.A.M.A. 1984; 251: 365–37410. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. J.A.M.A. 1984; 251: 365–374
   PubMed Web of Science ®Google Scholar
• Martin M. J., Hulley S. B., Browner W. S., Kuller L. H., Wentworth D. Serum cholesterol, blood pressure and mortality: implications from a cohort of 361, 662 men. Lancet 1986; 2: 933–93611. Martin M. J., Hulley S. B., Browner W. S., Kuller L. H., Wentworth D. Serum cholesterol, blood pressure and mortality: implications from a cohort of 361, 662 men. Lancet 1986; 2: 933–936
   PubMed Web of Science ®Google Scholar
• Pelkonen R., Nikkila E. A., Koskinen S., Penttinen K., Saru S. Association of serum lipids and obesity with cardiovascular mortality. Br. Med. J. 1977; 2: 1185–118712. Pelkonen R., Nikkila E. A., Koskinen S., Penttinen K., Saru S. Association of serum lipids and obesity with cardiovascular mortality. Br. Med. J. 1977; 2: 1185–1187
   PubMed Web of Science ®Google Scholar
• Ross J. The pathology of atherosclerosis - an update. N. Engl. J. Med. 1986; 314: 488–50013. Ross J. The pathology of atherosclerosis - an update. N. Engl. J. Med. 1986; 314: 488–500
   PubMed Web of Science ®Google Scholar
• Sirtori C. R., Gianfranceschi G., Sirtori M., Bernini F., Desocovich G., Montaguti V., Fuccella L. M., Musatti L. Reduced triglyceridaemia and increased high-density lipoprotein cholesterol levels after treatment with acipimox, a new inhibitor of lipolysis. Atherosclerosis 1981; 38: 267–27114. Sirtori C. R., Gianfranceschi G., Sirtori M., Bernini F., Desocovich G., Montaguti V., Fuccella L. M., Musatti L. Reduced triglyceridaemia and increased high-density lipoprotein cholesterol levels after treatment with acipimox, a new inhibitor of lipolysis. Atherosclerosis 1981; 38: 267–271
   PubMed Web of Science ®Google Scholar
• Sommariva D., Pogliaghi I., Bonfiglioll D., Cabrini E., Tirrito M., Lavezzari M. Changes in lipoprotein cholesterol and triglycerides induced by acipimox in Type IV and Type II hyperlipoproteinemic patients. Curr. Ther. Res. 1985; 37: 363–36815. Sommariva D., Pogliaghi I., Bonfiglioll D., Cabrini E., Tirrito M., Lavezzari M. Changes in lipoprotein cholesterol and triglycerides induced by acipimox in Type IV and Type II hyperlipoproteinemic patients. Curr. Ther. Res. 1985; 37: 363–368
   Web of Science ®Google Scholar
• Stamler J., Wentworth D., Neaton J. D. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356, 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). J.A.M.A. 1986; 256: 2823–282816. Stamler J., Wentworth D., Neaton J. D. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356, 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). J.A.M.A. 1986; 256: 2823–2828
   PubMed Web of Science ®Google Scholar